Thromboembolism associated with new anti-cancer treatment strategies in combination with conventional chemotherapy: new drugs, old risks?

• References

• 1 Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82: 4-6.
• 2 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
• 3 Relf M. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumour growth factor-β1, platelet-derived endothelial growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-9.
• 4 Yang JC, Haworth L, Steinberg SM. et al. A randomised double-blind placebo-controlled trial of bevacizumab anti-VEGF antibody demonstrating a prolongation time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol 2002; 21: 15
• 5 Hurwitz H., Fehrenbacher L., Cartwright T.. et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Program/Proceedings of the American Society of Clinical Oncology 2003 abstract 3646 (in press)
• 6 Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 1997; 14: 1-10.
• 7 Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 2003; 7: 385-97.
• 8 Liotta LA, Tryggvason K, Moor WGI. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8.
• 9 Itoh T, Tanioka M, Yoshida H. et al. Reduced angiogenesis and tumor progression in gelatinase-A deficient mice. Cancer Res 1998; 58: 1048-51.
• 10 Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma mouse model. Cancer Res 1996; 56: 5279-84.
• 11 Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors: trials and tribulations. Science 2002; 295: 2387-92.
• 12 Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomised to prinomastat or placebo, plus chemotherapy. Thromb Haemost 2003; 90: 734-7.
• 13 Keunen BC, Rosen L, Smit EF. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-67.
• 14 Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II, randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
• 15 Recio FO, Piver MS, Hempling RE. et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996; 78: 2157-63.
• 16 Caine GJ, Stonelake PS, Lip GYH. et al. The hypercoagulable state of malignancy; pathogenesis and current debate. Neoplasia 2002; 4: 465-73.
• 17 Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncology 2002; 3: 27-34.
• 18 Hamaad A, Tayebjee MH, Lip GYH. The METHRO trials. Expert Opin Investig Drugs 2003; 12 (05) 865-70.